X4 PHARMACEUTICALS, INC Payments for Securities Purchased under Agreements to Resell
X4 PHARMACEUTICALS, INC (XFOR) had Payments for Securities Purchased under Agreements to Resell of $3.00 million as of 2022-01-14, per its 10-K filed 2025-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForSecuritiesPurchasedUnderAgreementsToResell · last filed 2025-03-26
- 2022-01-14: Payments for Securities Purchased under Agreements to Resell $3.00M.
| Period end | Payments for Securities Purchased under Agreements to Resell |
|---|---|
| 2022-01-14 | $3.00M 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |